

---

**STALLERGENES GREER SECURES €50M REVOLVING CREDIT FACILITY****DATE: December 1, 2016**

London (United Kingdom) – Stallergenes Greer plc (the “Company”) (Euronext Paris: STAGR), a biopharmaceutical company specializing in treatments for respiratory allergies, today announced it secured a 50 million Euros revolving credit facility (the "Facility").

The facility - subject to customary closing conditions - will take the form of a revolving credit line composed of one single tranche, provided by UBS Switzerland AG.

The facility will be used for general corporate purposes.

**ABOUT STALLERGENES GREER PLC**

Headquartered in London (UK), Stallergenes Greer plc is a global healthcare company specializing in the diagnosis and treatment of allergies through the development and commercialization of allergy immunotherapy products and services. Stallergenes Greer plc is the parent company of GREER Laboratories, Inc. (whose registered office is in the U.S.) and Stallergenes S.A.S. (whose registered office is in France).

**Trading information:**

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification 4577

Market: Euronext Paris regulated market

Additional information is available at <http://www.stallergenesgreer.com>

*This document (including information incorporated by reference in this document), oral statements made and other information published by the Company contain statements that are or may be forward-looking with respect to the financial condition and/or results of operations and businesses of the Company. These statements can be identified by the use of forward-looking terminology such as "believe," "expects," "project," "estimated," "forecast," "should," "plan," "may" or the negative of any of these, or other variations thereof, or comparable terminology indicating expectations or beliefs concerning future events. These forward-looking statements include risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. These and other factors are more fully described in the Company's 2015 annual report published on 29 April 2016 on the Company's website ([www.stallergenesgreer.com](http://www.stallergenesgreer.com)). Actual results may differ from those set forth in the forward-looking statements, due to various factors. Save as required by applicable law, neither the Company nor any other person assumes any obligation to update these forward-looking statements or to notify any person of any such update.*

## **Contacts**

### **Investor and Analyst Relations**

Peter Bühler  
Chief Financial Officer  
Tel: +33 1 55 59 23 22  
Email: [investorrelations@aresallergyco.com](mailto:investorrelations@aresallergyco.com)

### **Investor Relations Agency**

FTI Consulting  
Arnaud de Cheffontaines  
Tel: +33 1 47 03 69 48  
Email: [arnaud.decheffontaines@fticonsulting.com](mailto:arnaud.decheffontaines@fticonsulting.com)

### **Media Relations**

Lise Lemonnier  
Head of Global Communications  
Tel: + 33 1 55 59 20 96  
Email: [llemonnier@stallergenes.com](mailto:llemonnier@stallergenes.com)

### **Media relations agency**

Havas Worldwide Paris  
Jean-Baptiste Froville  
Tel: +33 1 58 47 95 39  
Email: [jean-baptiste.froville@havasww.com](mailto:jean-baptiste.froville@havasww.com)